Skip to Main content Skip to Navigation

New therapeutic approaches for achondroplasia

Abstract : Missense mutations in the tyrosine kinase receptor FGFR3 (Fibroblast Growth Factor Receptor 3) lead to its overactivation causing biological dysfunctions in several diseases. Achondroplasia, the most common Fgfr3-related chondrodysplasia, is a rare genetic disorder, affecting 1 in 20000 live births, characterized by particular clinical features: rhizomelic dwarfism, short limbs, macrocephaly, midface hypoplasia, cervicomedullary compression. The abnormal activity of the receptor induces endochondral ossification defects that are responsible for the pathological phenotype. For a long time the only treatment for this disease was the limb lengthening surgery, however in recent years several researchers have developed potential therapeutic strategies based on molecular studies. The objective of my thesis was to evaluate a novel therapeutic approach for achondroplasia. A promising therapeutic strategy involved the use of small chemical inhibitors, known as tyrosine kinase inhibitors, that are able to arrest the FGFR3 activity. I have assessed the effects of one of these compounds, NVP-BGJ398, in a mouse model mimicking the acondroplastic dwarfism (Fgfr3Y367C/+). The experiments performed showed an improvement of all pathological hallmarks in NVP-BGJ398 treated mice. We have also inspected the impact of the activating FGFR3 mutation on the mandibular development. The study established a defect in mandibular growth in both affected patients and mice. Furthermore we could investigate the mandibular bone growth and correct the pathological defect with NVP-BGJ398. Finally I have participated in molecular analyses to describe how three FGFR3 mutations at the same position could lead to three different dwarfisms with increasing severity. The results provided a better understanding of FGFR3 pathological molecular mechanisms and could lead to new targets for therapeutic approaches.
Document type :
Complete list of metadatas
Contributor : Abes Star :  Contact
Submitted on : Monday, September 2, 2019 - 1:26:58 AM
Last modification on : Saturday, July 11, 2020 - 3:52:24 AM
Long-term archiving on: : Thursday, January 9, 2020 - 10:28:49 AM


Version validated by the jury (STAR)


  • HAL Id : tel-02275815, version 1


Davide Selom Komi Komla-Ebri. New therapeutic approaches for achondroplasia. Genetics. Université Sorbonne Paris Cité, 2016. English. ⟨NNT : 2016USPCB040⟩. ⟨tel-02275815⟩



Record views


Files downloads